BR0209785A - Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente - Google Patents

Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente

Info

Publication number
BR0209785A
BR0209785A BR0209785-0A BR0209785A BR0209785A BR 0209785 A BR0209785 A BR 0209785A BR 0209785 A BR0209785 A BR 0209785A BR 0209785 A BR0209785 A BR 0209785A
Authority
BR
Brazil
Prior art keywords
compound
solvates
pharmaceutically acceptable
esters
treating
Prior art date
Application number
BR0209785-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Francoise Jeanne Gellibert
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0209785A publication Critical patent/BR0209785A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
BR0209785-0A 2001-05-31 2002-05-29 Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente BR0209785A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113231.5A GB0113231D0 (en) 2001-05-31 2001-05-31 Chemical compounds
PCT/EP2002/005886 WO2002096895A1 (en) 2001-05-31 2002-05-29 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor

Publications (1)

Publication Number Publication Date
BR0209785A true BR0209785A (pt) 2004-06-01

Family

ID=9915636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209785-0A BR0209785A (pt) 2001-05-31 2002-05-29 Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente

Country Status (28)

Country Link
US (1) US7157479B2 (cg-RX-API-DMAC7.html)
EP (1) EP1399430B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004532267A (cg-RX-API-DMAC7.html)
KR (1) KR100859591B1 (cg-RX-API-DMAC7.html)
CN (1) CN1307166C (cg-RX-API-DMAC7.html)
AR (1) AR034051A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002317765B2 (cg-RX-API-DMAC7.html)
BR (1) BR0209785A (cg-RX-API-DMAC7.html)
CA (1) CA2448205A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540297A2 (cg-RX-API-DMAC7.html)
CY (1) CY1107206T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033252A3 (cg-RX-API-DMAC7.html)
DE (1) DE60223805T2 (cg-RX-API-DMAC7.html)
DK (1) DK1399430T3 (cg-RX-API-DMAC7.html)
ES (1) ES2296965T3 (cg-RX-API-DMAC7.html)
GB (1) GB0113231D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0400043A3 (cg-RX-API-DMAC7.html)
IL (1) IL158929A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03011032A (cg-RX-API-DMAC7.html)
MY (1) MY132656A (cg-RX-API-DMAC7.html)
NO (1) NO20035209L (cg-RX-API-DMAC7.html)
NZ (1) NZ529754A (cg-RX-API-DMAC7.html)
PL (1) PL367248A1 (cg-RX-API-DMAC7.html)
PT (1) PT1399430E (cg-RX-API-DMAC7.html)
SI (1) SI1399430T1 (cg-RX-API-DMAC7.html)
TW (1) TWI245760B (cg-RX-API-DMAC7.html)
WO (1) WO2002096895A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200309095B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003398A (es) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0323702D0 (en) * 2003-10-09 2003-11-12 Smithkline Beecham Corp Chemical compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
JP5357894B2 (ja) * 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
CN110803996B (zh) * 2019-11-13 2022-01-11 台州市创源工业技术有限公司 一种羟基苄胺的合成方法
CN116511225B (zh) * 2023-03-30 2025-09-23 江南大学 一种油酸基des液体及其制备方法和它在厌氧发酵液高效浓缩中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
NZ515087A (en) * 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CA2448205A1 (en) 2002-12-05
WO2002096895A1 (en) 2002-12-05
DE60223805D1 (de) 2008-01-10
HUP0400043A2 (hu) 2004-04-28
ES2296965T3 (es) 2008-05-01
US20050070517A1 (en) 2005-03-31
KR20040007632A (ko) 2004-01-24
CO5540297A2 (es) 2005-07-29
HK1064367A1 (en) 2005-01-28
NO20035209L (no) 2004-01-27
AU2002317765B2 (en) 2005-02-03
EP1399430A1 (en) 2004-03-24
CN1307166C (zh) 2007-03-28
GB0113231D0 (en) 2001-07-25
CY1107206T1 (el) 2012-11-21
DE60223805T2 (de) 2008-10-30
JP2004532267A (ja) 2004-10-21
MY132656A (en) 2007-10-31
EP1399430B1 (en) 2007-11-28
CN1633421A (zh) 2005-06-29
CZ20033252A3 (en) 2004-03-17
ZA200309095B (en) 2005-02-21
NO20035209D0 (no) 2003-11-24
TWI245760B (en) 2005-12-21
PL367248A1 (en) 2005-02-21
SI1399430T1 (sl) 2008-04-30
DK1399430T3 (da) 2008-03-25
IL158929A0 (en) 2004-05-12
AR034051A1 (es) 2004-01-21
PT1399430E (pt) 2008-02-19
KR100859591B1 (ko) 2008-09-23
HUP0400043A3 (en) 2008-03-28
US7157479B2 (en) 2007-01-02
MXPA03011032A (es) 2004-03-19
NZ529754A (en) 2005-12-23

Similar Documents

Publication Publication Date Title
BR0210077A (pt) Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa
BR0016067A (pt) Oxazóis substituìdos e derivados tiazóis como ativadores de hppar alfa
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
TW200510441A (en) Novel compounds
GB0111523D0 (en) Chemical compounds
WO2008005519A3 (en) Novel pyridazine compound and use thereof
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
RU2008132204A (ru) Соединения для лечения метаболических заболеваний
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
IT1311922B1 (it) Composti farmaceutici.
DK0565549T3 (da) Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B
IS6565A (is) Trópan afleiður nytsamlegar í meðferð
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
ATE332903T1 (de) Kondensierte pyridoindolderivate
ATE246196T1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
ATE497948T1 (de) Bicyclische verbindungen
BR0013112A (pt) Agentes antibacterianos
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
DE60112960D1 (de) Kondensierte pyridoindolderivate
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DE60126864D1 (de) Verfahren zur Herstellung von (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione und Analoge
MXPA03011032A (es) Activadores de derivados de oxazol/tiazol del receptor hppar-alfa.
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE269862T1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften
NZ221314A (en) 1,4-dihydropyridine derivatives and pharmaceutical composition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INTE.CL: C07D 277/56, A61K 31/42, A61K 31/425

Ipc: C07D 277/56 (2011.01), A61K 31/42 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.